The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems
Abstract Obesity (Ob) poses a significant risk factor for the onset of metabolic syndrome with associated complications, wherein the Mesenchymal Stem Cell (MSC) therapy shows pre-clinical success. Here, we explore the therapeutic applications of human Placental MSCs (P-MSCs) to address Ob-associated...
Guardado en:
Autores principales: | Nagasuryaprasad Kotikalapudi, Samuel Joshua Pragasam Sampath, Sinha Sukesh Narayan, Bhonde Ramesh R, Harishankar Nemani, Sathish Kumar Mungamuri, Vijayalakshmi Venkatesan |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0ddcc500f44e4b2686b49fe7751e74e2 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Author Correction: The promise(s) of mesenchymal stem cell therapy in averting preclinical diabetes: lessons from in vivo and in vitro model systems
por: Nagasuryaprasad Kotikalapudi, et al.
Publicado: (2021) -
Seward's Plan to Avert Civil War
Publicado: (2017) -
Mesenchymal stem cells as a platform for research on traditional medicine
por: Ramesh Bhonde, et al.
Publicado: (2021) -
Mesenchymal stem cell conditioned medium ameliorates diabetic serum-induced insulin resistance in 3T3-L1 cells
por: Avinash Sanap, et al.
Publicado: (2021) -
Demand for environmental quality: averting behaviors impacts and valuation in Southern Ghana
por: Charles Yaw Okyere
Publicado: (2021)